Pam McKay

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 707 citations · Full text

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

H. Miles Prince, Youn H. Kim, Reinhard Dummer et al. · The Lancet · 2017 · 569 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +9

Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial

Franck Morschhauser, Hervé Tilly, Aristeidis Chaidos et al. · The Lancet Oncology · 2020 · 556 citations · Full text

Lymphoid Neoplasia, Oncology, Malignant Blood Disorder +7

Detection of functional iron deficiency during erythropoietin treatment: a new approach.

Iain C. Macdougall, I. Cavill, B. Hulme et al. · BMJ · 1992 · 251 citations · Full text

Low Dose, Occupational Health Sciences, Iron Metabolism +28

The PROCLIPI international registry of early‐stage mycosis fungoides identifies substantial diagnostic delay in most patients

Julia Scarisbrick, Pietro Quaglino, H. Miles Prince et al. · British Journal of Dermatology · 2018 · 216 citations · Full text